Product
Dose Level 2B
1 clinical trial
3 indications
Indication
EBV-related non-Hodgkin's lymphomaClinical trial
Constitutive IL7 (C7R) Modified EBV Specific T-Lymphocytes for Treatment of EBV-Positive LymphomaStatus: Recruiting, Estimated PCD: 2024-03-30